Inpharma

Targeting the calcium-sensing receptor
pp. 2-2(1)

Aspirin worthwhile as primary CVD prevention in hypertension
pp. 3-3(1)

Pfizer's plans for torcetrapib highlight industry-driven approach
pp. 3-3(1)

Early intervention after MI may prevent sudden death
pp. 3-3(1)

Antibacterial prescribing strategies can reduce use in lower RTIs
pp. 4-4(1)

Orlistat eases burden in responding obese patients with DM
pp. 4-4(1)

Quetiapine a cost-effective option for AD
pp. 4-4(1)

SSRIs restore calm in panic disorder
pp. 5-5(1)

Achieving two-thirds reduction in child mortality by 2015 "affordable"
pp. 5-5(1)

Switch from brandname to generic clozapine pays dividends in the US
pp. 6-6(1)

Ivabradine: a new INITIATIVE in elderly with stable angina pectoris
pp. 6-6(1)

Cisplatin + topotecan does not reduce QOL in cervical cancer
pp. 6-6(1)

Sitaxsentan STRIDEs ahead in pulmonary arterial hypertension
pp. 7-8(2)

TRX 4 preserves residual -cell function in new-onset type 1 DM
pp. 8-8(1)

Monoclonal antibody G250 [WX G250] produces a long-term survival benefit in patients with stage IV metastatic renal cancer
pp. 8-8(1)

Avanafil is effective in patients with erectile dysfunction
pp. 8-8(1)

ER dexmethylphenidate beneficial in ADHD
pp. 9-9(1)

FTY 720 reduces relapse rate, disease activity in relapsing MS
pp. 9-9(1)

Gaboxadol significantly improves key sleep measures in patients with primary insomnia
pp. 9-9(1)

PEG IFN--2b + ribavirin: 12 weeks' worth could do the trick in HCV
pp. 10-10(1)

Antibacterial use justified in UTIs "irrespective of dipstick findings"
pp. 10-10(1)

Adjuvant cisplatin + vinorelbine: the new standard of care in NSCLC?
pp. 10-10(1)

The addition of colestilan to atorvastatin therapy further reduces LDL-cholesterol (LDL-C) in patients with familial hypercholesterolaemia
pp. 10-10(1)

Adalimumab a coming CLASSIC treatment for Crohn's disease
pp. 11-12(2)

Infanrix-HepB/Hib vaccine mix cuts the number of jabs for infants
pp. 12-12(1)

Tamsulosin, terazosin, doxazosin effective for ureteral calculi
pp. 12-12(1)

Gemcitabine + carboplatin beneficial in pancreatic cancer
pp. 12-12(1)

DTaP booster vaccine immunogenic in adolescents and adults
pp. 13-13(1)

Long-term infliximab appears to provide persistent clinical efficacy for patients with ankylosing spondylitis
pp. 13-13(1)

Quadramet has tumoricidal activity, palliative benefits in cancers
pp. 13-13(1)

Glatiramer acetate beats IFN- therapies for relapsing-remitting MS
pp. 13-13(1)

Duloxetine ± pelvic floor training effective in urinary incontinence
pp. 14-14(1)

Sildenafil puts its hand up for the treatment of PAH
pp. 14-14(1)

Combining cisplatin and topotecan improves survival in cervical cancer
pp. 14-14(1)

Treatment with doxycycline is effective in patients with Wuchereria bancrofti infections
pp. 14-14(1)

Irbesartan/hydrochlorothiazide an all-INCLUSIVE antihypertensive
pp. 15-16(2)

Intensive atorvastatin reduces CRP, LDL-C in acute coronary syndromes
pp. 16-16(1)

Long-term treatment with botulinum toxin is effective and is associated with a low incidence of immunogenicity
pp. 16-16(1)

N-acetylcysteine beneficial in COPD exacerbations
pp. 18-18(1)

An ocular antibacterial is not necessary at first presentation in healthy children with acute conjunctivitis
pp. 18-18(1)

Dual antiplatelet therapy with clopidogrel and aspirin is more effective than aspirin alone in reducing asymptomatic embolisation in patients with recently symptomatic carotid stenosis
pp. 18-18(1)

The combination of zinc gluconate and topical erythromycin appears to be an "interesting" treatment option for acne
pp. 18-18(1)

Treatment of oocytes with recombinant human hyaluronidase [Cumulase] produces a higher rate of fertilisation than bovine-derived hyaluronidase
pp. 18-18(1)

The pharmacokinetics (PK) of aprepitant are not affected in patients with end-stage renal disease (ESRD) or severe renal impairment
pp. 19-19(1)

Bigger is better for clopidogrel loading dose after stent placement
pp. 19-19(1)

Inhaled insulin [Exubera] has a faster onset of action than SC human insulin [Humulin] and the rapid-acting SC insulin lispro
pp. 19-19(1)

ACDC SNPs alter response to rosiglitazone in diabetes
pp. 19-19(1)

Ondansetron appears to antagonise lidocaine-induced sensory block in men receiving subarachnoid anaesthesia
pp. 20-20(1)

Greater QTc interval prolongation with droperidol a myth?
pp. 20-20(1)

EMEA recommends suspension of Bextra marketing in the EU
pp. 20-20(1)

US product launches
pp. 21-21(1)

US product approvals
pp. 21-21(1)

Other US regulatory news
pp. 21-21(1)

EU product launches
pp. 22-22(1)

Other EU regulatory news
pp. 22-22(1)

EU product approvals
pp. 22-22(1)

Product launches in Japan
pp. 22-22(1)

Other regulatory news from Japan
pp. 22-22(1)

Product Introductions
pp. 23-23(1)